Nicotine is addictive, and quitting smoking leads to symptoms of nicotine withdrawal such as craving, anxiety and irritability, depression, and weight gain. Professional smoking cessation support methods generally endeavor to address both nicotine addiction and nicotine withdrawal symptoms. Interventions such as nicotine replacement therapies (NRTs) work by delivering nicotine into the body to ease withdrawal while allowing the smoker to break the behavioral habits associated with the cigarette itself. The antidepressant bupropion is considered a first-line medication for smoking cessation and has been shown in many studies to increase long-term success rates. Varenicline decreases the urge to smoke and reduces withdrawal symptoms and is therefore considered a first-line medication for smoking cessation. Clonidine may reduce withdrawal symptoms and “approximately doubles abstinence rates when compared to a placebo,” but its side effects include dry mouth and sedation, and abruptly stopping the drug can cause high blood pressure and other side effects.
The global smoking cessation and nicotine de-addiction products market report estimates the market size (Revenue USD million – 2014 to 2021) for key market segments based on the product types (nicotine replacement therapy products – nicotine gums, nicotine inhalers, nicotine lozenges, nicotine sprays, nicotine sublingual tablets, nicotine transdermal patches; drug therapy – Chantix or champix, zyban; and e-cigarettes), and forecasts growth trends (CAGR% – 2017 to 2021).
The global smoking cessation and nicotine de-addiction products market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global smoking cessation and nicotine de-addiction products market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global smoking cessation and nicotine de-addiction products market and included in this report are Cipla, GSK, Johnson & Johnson, Pfizer, Revolymer plc, and Takeda Pharmaceuticals Co. Ltd.